背景:2019年冠状病毒病(COVID-19)为管理大流行提出了关键的诊断挑战。我们调查了从大流行早期到2022年京都市最近的Omicron激增的30个月来,COVID-19检测方式和功能测试地点的变化,日本。
方法:这是一项回顾性观察研究,使用当地匿名人群数据库,包括患者的人口统计学和临床信息,检测方法和设施从2020年1月至2022年6月,共30个月。我们计算了症状表现的分布,测试方法,和案件之间的测试设施。使用卡方检验独立性测试随时间的差异。
结果:在研究期间,报告了133,115例确诊的COVID-19病例,其中90.9%是有症状的。尽管核酸扩增检测占所有检测的68.9%,横向流动装置(LFD)的比率在2022年迅速增加。随着大流行的继续,检测能力从COVID-19指定的设施转移到全科医生,谁成为领先的测试提供商(2022年99,945项测试中的57.3%)。
结论:在京都大流行的前30个月,测试方式发生了动态变化。随着2022年LFD的使用急剧普及,全科医生的作用大大增加。通过理解和记录测试方法和测试地点的演变,预计这将有助于为下一次大流行建立更有效的测试基础设施。
The coronavirus disease 2019 (COVID-19) presents critical diagnostic challenges for managing the pandemic. We investigated the 30-month changes in COVID-19 testing modalities and functional testing sites from the early period of the pandemic to the most recent Omicron surge in 2022 in Kyoto City, Japan.
This is a retrospective-observational study using a local anonymized population database that included patients\' demographic and clinical information, testing methods and facilities from January 2020 to June 2022, a total of 30 months. We computed the distribution of symptomatic presentation, testing methods, and testing facilities among cases. Differences over time were tested using chi-square tests of independence.
During the study period, 133,115 confirmed COVID-19 cases were reported, of which 90.9% were symptomatic. Although nucleic acid amplification testing occupied 68.9% of all testing, the ratio of lateral flow devices (LFDs) rapidly increased in 2022. As the pandemic continued, the testing capability was shifted from COVID-19 designated facilities to general practitioners, who became the leading testing providers (57.3% of 99,945 tests in 2022).
There was a dynamic shift in testing modality during the first 30 months of the pandemic in Kyoto City. General practitioners increased their role substantially as the use of LFDs spread dramatically in 2022. By comprehending and documenting the evolution of testing methods and testing locations, it is anticipated that this will contribute to the establishment of an even more efficient testing infrastructure for the next pandemic.